Cytoreductive surgery for head and neck squamous cell carcinoma in the new age of immunotherapy
• Patients who develop local-regional disease progression in conjunction with distant metastasis have few good palliative options available to achieve local tumor control and/or relieve symptoms. • The goal of cytoreductive surgery is to minimize tumor-induced immune suppression by reducing the numb...
Ausführliche Beschreibung
Gespeichert in:
| Autor*in: |
Bell, R. Bryan [verfasserIn] |
|---|
| Format: |
E-Artikel |
|---|---|
| Sprache: |
Englisch |
| Erschienen: |
2016 |
|---|
| Schlagwörter: |
|---|
| Umfang: |
11 |
|---|
| Übergeordnetes Werk: |
Enthalten in: Anti-anaerobic activity of a new β-lactamase inhibitor NXL104 in combination with β-lactams and metronidazole - 2012transfer abstract, Amsterdam [u.a.] |
|---|---|
| Übergeordnetes Werk: |
volume:61 ; year:2016 ; pages:166-176 ; extent:11 |
| Links: |
|---|
| DOI / URN: |
10.1016/j.oraloncology.2016.08.020 |
|---|
| Katalog-ID: |
ELV035030976 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | ELV035030976 | ||
| 003 | DE-627 | ||
| 005 | 20230624020402.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 180603s2016 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.oraloncology.2016.08.020 |2 doi | |
| 028 | 5 | 2 | |a GBVA2016002000023.pica |
| 035 | |a (DE-627)ELV035030976 | ||
| 035 | |a (ELSEVIER)S1368-8375(16)30149-X | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | |a 610 | |
| 082 | 0 | 4 | |a 610 |q DE-600 |
| 082 | 0 | 4 | |a 610 |q VZ |
| 082 | 0 | 4 | |a 650 |q VZ |
| 084 | |a 85.03 |2 bkl | ||
| 084 | |a 31.80 |2 bkl | ||
| 084 | |a 54.80 |2 bkl | ||
| 084 | |a 50.03 |2 bkl | ||
| 100 | 1 | |a Bell, R. Bryan |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Cytoreductive surgery for head and neck squamous cell carcinoma in the new age of immunotherapy |
| 264 | 1 | |c 2016 | |
| 300 | |a 11 | ||
| 336 | |a nicht spezifiziert |b zzz |2 rdacontent | ||
| 337 | |a nicht spezifiziert |b z |2 rdamedia | ||
| 338 | |a nicht spezifiziert |b zu |2 rdacarrier | ||
| 520 | |a • Patients who develop local-regional disease progression in conjunction with distant metastasis have few good palliative options available to achieve local tumor control and/or relieve symptoms. • The goal of cytoreductive surgery is to minimize tumor-induced immune suppression by reducing the number of cancer cells via resection of primary tumor or metastatic deposits, to palliate symptoms, and prevent complications. • We hypothesize that surgical resection can be combined with immunotherapy to induce an effective immune response and overcome immunosuppression in the tumor microenvironment. | ||
| 650 | 7 | |a Oral cancer |2 Elsevier | |
| 650 | 7 | |a Immunotherapy |2 Elsevier | |
| 650 | 7 | |a Surgery |2 Elsevier | |
| 650 | 7 | |a Cytoreductive |2 Elsevier | |
| 650 | 7 | |a Head and neck cancer |2 Elsevier | |
| 650 | 7 | |a Cancer |2 Elsevier | |
| 700 | 1 | |a Gough, Michael J. |4 oth | |
| 700 | 1 | |a Seung, Steven K. |4 oth | |
| 700 | 1 | |a Jutric, Zeljka |4 oth | |
| 700 | 1 | |a Weinberg, Andrew D. |4 oth | |
| 700 | 1 | |a Fox, Bernard A. |4 oth | |
| 700 | 1 | |a Crittenden, Marka R. |4 oth | |
| 700 | 1 | |a Leidner, Rom S. |4 oth | |
| 700 | 1 | |a Curti, Brendan |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |n Elsevier Science |t Anti-anaerobic activity of a new β-lactamase inhibitor NXL104 in combination with β-lactams and metronidazole |d 2012transfer abstract |g Amsterdam [u.a.] |w (DE-627)ELV011194073 |
| 773 | 1 | 8 | |g volume:61 |g year:2016 |g pages:166-176 |g extent:11 |
| 856 | 4 | 0 | |u https://doi.org/10.1016/j.oraloncology.2016.08.020 |3 Volltext |
| 912 | |a GBV_USEFLAG_U | ||
| 912 | |a GBV_ELV | ||
| 912 | |a SYSFLAG_U | ||
| 912 | |a SSG-OPC-MAT | ||
| 936 | b | k | |a 85.03 |j Methoden und Techniken der Betriebswirtschaft |q VZ |
| 936 | b | k | |a 31.80 |j Angewandte Mathematik |q VZ |
| 936 | b | k | |a 54.80 |j Angewandte Informatik |q VZ |
| 936 | b | k | |a 50.03 |j Methoden und Techniken der Ingenieurwissenschaften |q VZ |
| 951 | |a AR | ||
| 952 | |d 61 |j 2016 |h 166-176 |g 11 | ||
| 953 | |2 045F |a 610 | ||
| author_variant |
r b b rb rbb |
|---|---|
| matchkey_str |
bellrbryangoughmichaeljseungstevenkjutri:2016----:yoeutvsreyohaadekqaoselacnmite |
| hierarchy_sort_str |
2016 |
| bklnumber |
85.03 31.80 54.80 50.03 |
| publishDate |
2016 |
| allfields |
10.1016/j.oraloncology.2016.08.020 doi GBVA2016002000023.pica (DE-627)ELV035030976 (ELSEVIER)S1368-8375(16)30149-X DE-627 ger DE-627 rakwb eng 610 610 DE-600 610 VZ 650 VZ 85.03 bkl 31.80 bkl 54.80 bkl 50.03 bkl Bell, R. Bryan verfasserin aut Cytoreductive surgery for head and neck squamous cell carcinoma in the new age of immunotherapy 2016 11 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier • Patients who develop local-regional disease progression in conjunction with distant metastasis have few good palliative options available to achieve local tumor control and/or relieve symptoms. • The goal of cytoreductive surgery is to minimize tumor-induced immune suppression by reducing the number of cancer cells via resection of primary tumor or metastatic deposits, to palliate symptoms, and prevent complications. • We hypothesize that surgical resection can be combined with immunotherapy to induce an effective immune response and overcome immunosuppression in the tumor microenvironment. Oral cancer Elsevier Immunotherapy Elsevier Surgery Elsevier Cytoreductive Elsevier Head and neck cancer Elsevier Cancer Elsevier Gough, Michael J. oth Seung, Steven K. oth Jutric, Zeljka oth Weinberg, Andrew D. oth Fox, Bernard A. oth Crittenden, Marka R. oth Leidner, Rom S. oth Curti, Brendan oth Enthalten in Elsevier Science Anti-anaerobic activity of a new β-lactamase inhibitor NXL104 in combination with β-lactams and metronidazole 2012transfer abstract Amsterdam [u.a.] (DE-627)ELV011194073 volume:61 year:2016 pages:166-176 extent:11 https://doi.org/10.1016/j.oraloncology.2016.08.020 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OPC-MAT 85.03 Methoden und Techniken der Betriebswirtschaft VZ 31.80 Angewandte Mathematik VZ 54.80 Angewandte Informatik VZ 50.03 Methoden und Techniken der Ingenieurwissenschaften VZ AR 61 2016 166-176 11 045F 610 |
| spelling |
10.1016/j.oraloncology.2016.08.020 doi GBVA2016002000023.pica (DE-627)ELV035030976 (ELSEVIER)S1368-8375(16)30149-X DE-627 ger DE-627 rakwb eng 610 610 DE-600 610 VZ 650 VZ 85.03 bkl 31.80 bkl 54.80 bkl 50.03 bkl Bell, R. Bryan verfasserin aut Cytoreductive surgery for head and neck squamous cell carcinoma in the new age of immunotherapy 2016 11 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier • Patients who develop local-regional disease progression in conjunction with distant metastasis have few good palliative options available to achieve local tumor control and/or relieve symptoms. • The goal of cytoreductive surgery is to minimize tumor-induced immune suppression by reducing the number of cancer cells via resection of primary tumor or metastatic deposits, to palliate symptoms, and prevent complications. • We hypothesize that surgical resection can be combined with immunotherapy to induce an effective immune response and overcome immunosuppression in the tumor microenvironment. Oral cancer Elsevier Immunotherapy Elsevier Surgery Elsevier Cytoreductive Elsevier Head and neck cancer Elsevier Cancer Elsevier Gough, Michael J. oth Seung, Steven K. oth Jutric, Zeljka oth Weinberg, Andrew D. oth Fox, Bernard A. oth Crittenden, Marka R. oth Leidner, Rom S. oth Curti, Brendan oth Enthalten in Elsevier Science Anti-anaerobic activity of a new β-lactamase inhibitor NXL104 in combination with β-lactams and metronidazole 2012transfer abstract Amsterdam [u.a.] (DE-627)ELV011194073 volume:61 year:2016 pages:166-176 extent:11 https://doi.org/10.1016/j.oraloncology.2016.08.020 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OPC-MAT 85.03 Methoden und Techniken der Betriebswirtschaft VZ 31.80 Angewandte Mathematik VZ 54.80 Angewandte Informatik VZ 50.03 Methoden und Techniken der Ingenieurwissenschaften VZ AR 61 2016 166-176 11 045F 610 |
| allfields_unstemmed |
10.1016/j.oraloncology.2016.08.020 doi GBVA2016002000023.pica (DE-627)ELV035030976 (ELSEVIER)S1368-8375(16)30149-X DE-627 ger DE-627 rakwb eng 610 610 DE-600 610 VZ 650 VZ 85.03 bkl 31.80 bkl 54.80 bkl 50.03 bkl Bell, R. Bryan verfasserin aut Cytoreductive surgery for head and neck squamous cell carcinoma in the new age of immunotherapy 2016 11 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier • Patients who develop local-regional disease progression in conjunction with distant metastasis have few good palliative options available to achieve local tumor control and/or relieve symptoms. • The goal of cytoreductive surgery is to minimize tumor-induced immune suppression by reducing the number of cancer cells via resection of primary tumor or metastatic deposits, to palliate symptoms, and prevent complications. • We hypothesize that surgical resection can be combined with immunotherapy to induce an effective immune response and overcome immunosuppression in the tumor microenvironment. Oral cancer Elsevier Immunotherapy Elsevier Surgery Elsevier Cytoreductive Elsevier Head and neck cancer Elsevier Cancer Elsevier Gough, Michael J. oth Seung, Steven K. oth Jutric, Zeljka oth Weinberg, Andrew D. oth Fox, Bernard A. oth Crittenden, Marka R. oth Leidner, Rom S. oth Curti, Brendan oth Enthalten in Elsevier Science Anti-anaerobic activity of a new β-lactamase inhibitor NXL104 in combination with β-lactams and metronidazole 2012transfer abstract Amsterdam [u.a.] (DE-627)ELV011194073 volume:61 year:2016 pages:166-176 extent:11 https://doi.org/10.1016/j.oraloncology.2016.08.020 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OPC-MAT 85.03 Methoden und Techniken der Betriebswirtschaft VZ 31.80 Angewandte Mathematik VZ 54.80 Angewandte Informatik VZ 50.03 Methoden und Techniken der Ingenieurwissenschaften VZ AR 61 2016 166-176 11 045F 610 |
| allfieldsGer |
10.1016/j.oraloncology.2016.08.020 doi GBVA2016002000023.pica (DE-627)ELV035030976 (ELSEVIER)S1368-8375(16)30149-X DE-627 ger DE-627 rakwb eng 610 610 DE-600 610 VZ 650 VZ 85.03 bkl 31.80 bkl 54.80 bkl 50.03 bkl Bell, R. Bryan verfasserin aut Cytoreductive surgery for head and neck squamous cell carcinoma in the new age of immunotherapy 2016 11 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier • Patients who develop local-regional disease progression in conjunction with distant metastasis have few good palliative options available to achieve local tumor control and/or relieve symptoms. • The goal of cytoreductive surgery is to minimize tumor-induced immune suppression by reducing the number of cancer cells via resection of primary tumor or metastatic deposits, to palliate symptoms, and prevent complications. • We hypothesize that surgical resection can be combined with immunotherapy to induce an effective immune response and overcome immunosuppression in the tumor microenvironment. Oral cancer Elsevier Immunotherapy Elsevier Surgery Elsevier Cytoreductive Elsevier Head and neck cancer Elsevier Cancer Elsevier Gough, Michael J. oth Seung, Steven K. oth Jutric, Zeljka oth Weinberg, Andrew D. oth Fox, Bernard A. oth Crittenden, Marka R. oth Leidner, Rom S. oth Curti, Brendan oth Enthalten in Elsevier Science Anti-anaerobic activity of a new β-lactamase inhibitor NXL104 in combination with β-lactams and metronidazole 2012transfer abstract Amsterdam [u.a.] (DE-627)ELV011194073 volume:61 year:2016 pages:166-176 extent:11 https://doi.org/10.1016/j.oraloncology.2016.08.020 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OPC-MAT 85.03 Methoden und Techniken der Betriebswirtschaft VZ 31.80 Angewandte Mathematik VZ 54.80 Angewandte Informatik VZ 50.03 Methoden und Techniken der Ingenieurwissenschaften VZ AR 61 2016 166-176 11 045F 610 |
| allfieldsSound |
10.1016/j.oraloncology.2016.08.020 doi GBVA2016002000023.pica (DE-627)ELV035030976 (ELSEVIER)S1368-8375(16)30149-X DE-627 ger DE-627 rakwb eng 610 610 DE-600 610 VZ 650 VZ 85.03 bkl 31.80 bkl 54.80 bkl 50.03 bkl Bell, R. Bryan verfasserin aut Cytoreductive surgery for head and neck squamous cell carcinoma in the new age of immunotherapy 2016 11 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier • Patients who develop local-regional disease progression in conjunction with distant metastasis have few good palliative options available to achieve local tumor control and/or relieve symptoms. • The goal of cytoreductive surgery is to minimize tumor-induced immune suppression by reducing the number of cancer cells via resection of primary tumor or metastatic deposits, to palliate symptoms, and prevent complications. • We hypothesize that surgical resection can be combined with immunotherapy to induce an effective immune response and overcome immunosuppression in the tumor microenvironment. Oral cancer Elsevier Immunotherapy Elsevier Surgery Elsevier Cytoreductive Elsevier Head and neck cancer Elsevier Cancer Elsevier Gough, Michael J. oth Seung, Steven K. oth Jutric, Zeljka oth Weinberg, Andrew D. oth Fox, Bernard A. oth Crittenden, Marka R. oth Leidner, Rom S. oth Curti, Brendan oth Enthalten in Elsevier Science Anti-anaerobic activity of a new β-lactamase inhibitor NXL104 in combination with β-lactams and metronidazole 2012transfer abstract Amsterdam [u.a.] (DE-627)ELV011194073 volume:61 year:2016 pages:166-176 extent:11 https://doi.org/10.1016/j.oraloncology.2016.08.020 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OPC-MAT 85.03 Methoden und Techniken der Betriebswirtschaft VZ 31.80 Angewandte Mathematik VZ 54.80 Angewandte Informatik VZ 50.03 Methoden und Techniken der Ingenieurwissenschaften VZ AR 61 2016 166-176 11 045F 610 |
| language |
English |
| source |
Enthalten in Anti-anaerobic activity of a new β-lactamase inhibitor NXL104 in combination with β-lactams and metronidazole Amsterdam [u.a.] volume:61 year:2016 pages:166-176 extent:11 |
| sourceStr |
Enthalten in Anti-anaerobic activity of a new β-lactamase inhibitor NXL104 in combination with β-lactams and metronidazole Amsterdam [u.a.] volume:61 year:2016 pages:166-176 extent:11 |
| format_phy_str_mv |
Article |
| bklname |
Methoden und Techniken der Betriebswirtschaft Angewandte Mathematik Angewandte Informatik Methoden und Techniken der Ingenieurwissenschaften |
| institution |
findex.gbv.de |
| topic_facet |
Oral cancer Immunotherapy Surgery Cytoreductive Head and neck cancer Cancer |
| dewey-raw |
610 |
| isfreeaccess_bool |
false |
| container_title |
Anti-anaerobic activity of a new β-lactamase inhibitor NXL104 in combination with β-lactams and metronidazole |
| authorswithroles_txt_mv |
Bell, R. Bryan @@aut@@ Gough, Michael J. @@oth@@ Seung, Steven K. @@oth@@ Jutric, Zeljka @@oth@@ Weinberg, Andrew D. @@oth@@ Fox, Bernard A. @@oth@@ Crittenden, Marka R. @@oth@@ Leidner, Rom S. @@oth@@ Curti, Brendan @@oth@@ |
| publishDateDaySort_date |
2016-01-01T00:00:00Z |
| hierarchy_top_id |
ELV011194073 |
| dewey-sort |
3610 |
| id |
ELV035030976 |
| language_de |
englisch |
| fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">ELV035030976</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230624020402.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">180603s2016 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1016/j.oraloncology.2016.08.020</subfield><subfield code="2">doi</subfield></datafield><datafield tag="028" ind1="5" ind2="2"><subfield code="a">GBVA2016002000023.pica</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)ELV035030976</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ELSEVIER)S1368-8375(16)30149-X</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">610</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">DE-600</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">650</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">85.03</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">31.80</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">54.80</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">50.03</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Bell, R. Bryan</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Cytoreductive surgery for head and neck squamous cell carcinoma in the new age of immunotherapy</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2016</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">11</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">• Patients who develop local-regional disease progression in conjunction with distant metastasis have few good palliative options available to achieve local tumor control and/or relieve symptoms. • The goal of cytoreductive surgery is to minimize tumor-induced immune suppression by reducing the number of cancer cells via resection of primary tumor or metastatic deposits, to palliate symptoms, and prevent complications. • We hypothesize that surgical resection can be combined with immunotherapy to induce an effective immune response and overcome immunosuppression in the tumor microenvironment.</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Oral cancer</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Immunotherapy</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Surgery</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Cytoreductive</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Head and neck cancer</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Cancer</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Gough, Michael J.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Seung, Steven K.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Jutric, Zeljka</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Weinberg, Andrew D.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Fox, Bernard A.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Crittenden, Marka R.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Leidner, Rom S.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Curti, Brendan</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="n">Elsevier Science</subfield><subfield code="t">Anti-anaerobic activity of a new β-lactamase inhibitor NXL104 in combination with β-lactams and metronidazole</subfield><subfield code="d">2012transfer abstract</subfield><subfield code="g">Amsterdam [u.a.]</subfield><subfield code="w">(DE-627)ELV011194073</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:61</subfield><subfield code="g">year:2016</subfield><subfield code="g">pages:166-176</subfield><subfield code="g">extent:11</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1016/j.oraloncology.2016.08.020</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ELV</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OPC-MAT</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">85.03</subfield><subfield code="j">Methoden und Techniken der Betriebswirtschaft</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">31.80</subfield><subfield code="j">Angewandte Mathematik</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">54.80</subfield><subfield code="j">Angewandte Informatik</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">50.03</subfield><subfield code="j">Methoden und Techniken der Ingenieurwissenschaften</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">61</subfield><subfield code="j">2016</subfield><subfield code="h">166-176</subfield><subfield code="g">11</subfield></datafield><datafield tag="953" ind1=" " ind2=" "><subfield code="2">045F</subfield><subfield code="a">610</subfield></datafield></record></collection>
|
| author |
Bell, R. Bryan |
| spellingShingle |
Bell, R. Bryan ddc 610 ddc 650 bkl 85.03 bkl 31.80 bkl 54.80 bkl 50.03 Elsevier Oral cancer Elsevier Immunotherapy Elsevier Surgery Elsevier Cytoreductive Elsevier Head and neck cancer Elsevier Cancer Cytoreductive surgery for head and neck squamous cell carcinoma in the new age of immunotherapy |
| authorStr |
Bell, R. Bryan |
| ppnlink_with_tag_str_mv |
@@773@@(DE-627)ELV011194073 |
| format |
electronic Article |
| dewey-ones |
610 - Medicine & health 650 - Management & auxiliary services |
| delete_txt_mv |
keep |
| author_role |
aut |
| collection |
elsevier |
| remote_str |
true |
| illustrated |
Not Illustrated |
| topic_title |
610 610 DE-600 610 VZ 650 VZ 85.03 bkl 31.80 bkl 54.80 bkl 50.03 bkl Cytoreductive surgery for head and neck squamous cell carcinoma in the new age of immunotherapy Oral cancer Elsevier Immunotherapy Elsevier Surgery Elsevier Cytoreductive Elsevier Head and neck cancer Elsevier Cancer Elsevier |
| topic |
ddc 610 ddc 650 bkl 85.03 bkl 31.80 bkl 54.80 bkl 50.03 Elsevier Oral cancer Elsevier Immunotherapy Elsevier Surgery Elsevier Cytoreductive Elsevier Head and neck cancer Elsevier Cancer |
| topic_unstemmed |
ddc 610 ddc 650 bkl 85.03 bkl 31.80 bkl 54.80 bkl 50.03 Elsevier Oral cancer Elsevier Immunotherapy Elsevier Surgery Elsevier Cytoreductive Elsevier Head and neck cancer Elsevier Cancer |
| topic_browse |
ddc 610 ddc 650 bkl 85.03 bkl 31.80 bkl 54.80 bkl 50.03 Elsevier Oral cancer Elsevier Immunotherapy Elsevier Surgery Elsevier Cytoreductive Elsevier Head and neck cancer Elsevier Cancer |
| format_facet |
Elektronische Aufsätze Aufsätze Elektronische Ressource |
| format_main_str_mv |
Text Zeitschrift/Artikel |
| carriertype_str_mv |
zu |
| author2_variant |
m j g mj mjg s k s sk sks z j zj a d w ad adw b a f ba baf m r c mr mrc r s l rs rsl b c bc |
| hierarchy_parent_title |
Anti-anaerobic activity of a new β-lactamase inhibitor NXL104 in combination with β-lactams and metronidazole |
| hierarchy_parent_id |
ELV011194073 |
| dewey-tens |
610 - Medicine & health 650 - Management & public relations |
| hierarchy_top_title |
Anti-anaerobic activity of a new β-lactamase inhibitor NXL104 in combination with β-lactams and metronidazole |
| isfreeaccess_txt |
false |
| familylinks_str_mv |
(DE-627)ELV011194073 |
| title |
Cytoreductive surgery for head and neck squamous cell carcinoma in the new age of immunotherapy |
| ctrlnum |
(DE-627)ELV035030976 (ELSEVIER)S1368-8375(16)30149-X |
| title_full |
Cytoreductive surgery for head and neck squamous cell carcinoma in the new age of immunotherapy |
| author_sort |
Bell, R. Bryan |
| journal |
Anti-anaerobic activity of a new β-lactamase inhibitor NXL104 in combination with β-lactams and metronidazole |
| journalStr |
Anti-anaerobic activity of a new β-lactamase inhibitor NXL104 in combination with β-lactams and metronidazole |
| lang_code |
eng |
| isOA_bool |
false |
| dewey-hundreds |
600 - Technology |
| recordtype |
marc |
| publishDateSort |
2016 |
| contenttype_str_mv |
zzz |
| container_start_page |
166 |
| author_browse |
Bell, R. Bryan |
| container_volume |
61 |
| physical |
11 |
| class |
610 610 DE-600 610 VZ 650 VZ 85.03 bkl 31.80 bkl 54.80 bkl 50.03 bkl |
| format_se |
Elektronische Aufsätze |
| author-letter |
Bell, R. Bryan |
| doi_str_mv |
10.1016/j.oraloncology.2016.08.020 |
| dewey-full |
610 650 |
| title_sort |
cytoreductive surgery for head and neck squamous cell carcinoma in the new age of immunotherapy |
| title_auth |
Cytoreductive surgery for head and neck squamous cell carcinoma in the new age of immunotherapy |
| abstract |
• Patients who develop local-regional disease progression in conjunction with distant metastasis have few good palliative options available to achieve local tumor control and/or relieve symptoms. • The goal of cytoreductive surgery is to minimize tumor-induced immune suppression by reducing the number of cancer cells via resection of primary tumor or metastatic deposits, to palliate symptoms, and prevent complications. • We hypothesize that surgical resection can be combined with immunotherapy to induce an effective immune response and overcome immunosuppression in the tumor microenvironment. |
| abstractGer |
• Patients who develop local-regional disease progression in conjunction with distant metastasis have few good palliative options available to achieve local tumor control and/or relieve symptoms. • The goal of cytoreductive surgery is to minimize tumor-induced immune suppression by reducing the number of cancer cells via resection of primary tumor or metastatic deposits, to palliate symptoms, and prevent complications. • We hypothesize that surgical resection can be combined with immunotherapy to induce an effective immune response and overcome immunosuppression in the tumor microenvironment. |
| abstract_unstemmed |
• Patients who develop local-regional disease progression in conjunction with distant metastasis have few good palliative options available to achieve local tumor control and/or relieve symptoms. • The goal of cytoreductive surgery is to minimize tumor-induced immune suppression by reducing the number of cancer cells via resection of primary tumor or metastatic deposits, to palliate symptoms, and prevent complications. • We hypothesize that surgical resection can be combined with immunotherapy to induce an effective immune response and overcome immunosuppression in the tumor microenvironment. |
| collection_details |
GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OPC-MAT |
| title_short |
Cytoreductive surgery for head and neck squamous cell carcinoma in the new age of immunotherapy |
| url |
https://doi.org/10.1016/j.oraloncology.2016.08.020 |
| remote_bool |
true |
| author2 |
Gough, Michael J. Seung, Steven K. Jutric, Zeljka Weinberg, Andrew D. Fox, Bernard A. Crittenden, Marka R. Leidner, Rom S. Curti, Brendan |
| author2Str |
Gough, Michael J. Seung, Steven K. Jutric, Zeljka Weinberg, Andrew D. Fox, Bernard A. Crittenden, Marka R. Leidner, Rom S. Curti, Brendan |
| ppnlink |
ELV011194073 |
| mediatype_str_mv |
z |
| isOA_txt |
false |
| hochschulschrift_bool |
false |
| author2_role |
oth oth oth oth oth oth oth oth |
| doi_str |
10.1016/j.oraloncology.2016.08.020 |
| up_date |
2024-07-06T22:37:35.374Z |
| _version_ |
1803871013175296000 |
| fullrecord_marcxml |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">ELV035030976</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230624020402.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">180603s2016 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1016/j.oraloncology.2016.08.020</subfield><subfield code="2">doi</subfield></datafield><datafield tag="028" ind1="5" ind2="2"><subfield code="a">GBVA2016002000023.pica</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)ELV035030976</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ELSEVIER)S1368-8375(16)30149-X</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">610</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">DE-600</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">650</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">85.03</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">31.80</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">54.80</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">50.03</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Bell, R. Bryan</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Cytoreductive surgery for head and neck squamous cell carcinoma in the new age of immunotherapy</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2016</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">11</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">• Patients who develop local-regional disease progression in conjunction with distant metastasis have few good palliative options available to achieve local tumor control and/or relieve symptoms. • The goal of cytoreductive surgery is to minimize tumor-induced immune suppression by reducing the number of cancer cells via resection of primary tumor or metastatic deposits, to palliate symptoms, and prevent complications. • We hypothesize that surgical resection can be combined with immunotherapy to induce an effective immune response and overcome immunosuppression in the tumor microenvironment.</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Oral cancer</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Immunotherapy</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Surgery</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Cytoreductive</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Head and neck cancer</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Cancer</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Gough, Michael J.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Seung, Steven K.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Jutric, Zeljka</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Weinberg, Andrew D.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Fox, Bernard A.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Crittenden, Marka R.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Leidner, Rom S.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Curti, Brendan</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="n">Elsevier Science</subfield><subfield code="t">Anti-anaerobic activity of a new β-lactamase inhibitor NXL104 in combination with β-lactams and metronidazole</subfield><subfield code="d">2012transfer abstract</subfield><subfield code="g">Amsterdam [u.a.]</subfield><subfield code="w">(DE-627)ELV011194073</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:61</subfield><subfield code="g">year:2016</subfield><subfield code="g">pages:166-176</subfield><subfield code="g">extent:11</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1016/j.oraloncology.2016.08.020</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ELV</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OPC-MAT</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">85.03</subfield><subfield code="j">Methoden und Techniken der Betriebswirtschaft</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">31.80</subfield><subfield code="j">Angewandte Mathematik</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">54.80</subfield><subfield code="j">Angewandte Informatik</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">50.03</subfield><subfield code="j">Methoden und Techniken der Ingenieurwissenschaften</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">61</subfield><subfield code="j">2016</subfield><subfield code="h">166-176</subfield><subfield code="g">11</subfield></datafield><datafield tag="953" ind1=" " ind2=" "><subfield code="2">045F</subfield><subfield code="a">610</subfield></datafield></record></collection>
|
| score |
7.399867 |